Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-07-11
2006-07-11
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C530S300000, C530S305000, C530S324000, C530S325000
Reexamination Certificate
active
07074415
ABSTRACT:
Streptococcuspolypeptides and polynucleotides encoding them are disclosed. The polypeptides may be useful vaccine components for the prophylaxis or therapy ofstreptococcusinfection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detectingstreptococcusbacterial infection.
REFERENCES:
patent: 6582706 (2003-06-01), Johnson et al.
patent: 6800744 (2004-10-01), Doucette-Stamm et al.
patent: 2003/0232976 (2003-12-01), Hamel et al.
patent: 2004/0081662 (2004-04-01), Hermand et al.
patent: WO/98/18930 (1998-05-01), None
patent: WO 98/18930 (1998-05-01), None
patent: WO/98/18931 (1998-05-01), None
patent: WO/99/15675 (1999-04-01), None
patent: WO00/06737 (2000-02-01), None
patent: WO00/06738 (2000-02-01), None
patent: WO00/17370 (2000-03-01), None
patent: 00/37105 (2000-06-01), None
patent: WO00/39299 (2000-07-01), None
patent: 00/76540 (2000-12-01), None
patent: 01/14421 (2001-03-01), None
patent: WO01/98334 (2001-12-01), None
patent: WO02/077021 (2002-10-01), None
patent: WO04/09229 (2004-10-01), None
Orihuela et al, Scandinavian Journal of Infectious Diseases, Vo. 35, No. 9, 2003, p. 647-652.
Whittam et al, Current Opinion in Genetics and Development, Dec. 2002, vol. 12, No. 6.
Sa-Leao et al, Abstracts of the General Meeting of the American Society for Microbiology, May 20-24, 20.
Thomas E. Creighton, in his book, “Proteins: Structures and Molecular Properties, 1984”, (p. 315).
Thomas E. Creighton, in his book “Protein Structure: A Practical Approach, 1989; pp. 184-186”.
Nosoh, Y. et al in “Protein Stability and Stabilization through Protein Engineering, 1991” (chapter 7, p. 197, second paragraph.
Oli et al (Infection and Immunity, Dec. 2004, p. 6951-6960).
Ellis (Vaccines, W.B. Saunders Company, Chapter 29, 1988, pp. 568-574).
Boslego et al (Vaccines and Immunotherapy, 1991, Chapter 17).
Swildens et al (Veterinary Microbiology 103, 2004, 29-33).
Bolton et al (Can J. Microbiol., Jun. 2004, 50(6):423-32). (Abstract only).
Okamoto et al (Vaccine 22 (2004) 2887-2893).
Boslego et al. “Vaccines And Immunotherapy” Pergamon Press, 1991, Chapter 17, pp. 211-223.
Ellis, et al. “New Technologies for Making Vaccines,” WB Sanders Co., 1988, Chapter 29, pp. 568-575.
Briles D.E. et al, Immunization of Humans with Recombinant Pneumococcal Surface Protein A (rPsspA) Elicits Antibodies that Passively Protect Mice from Fatal Infection withStreptococcus pneumoniaebearing Heterologous PspA J Infectious Disease 182 (Dec. 2000) 1694-1701.
Briles, D.E. et al, Intranasal Immunization of Mice with a Mixture of the Pneumococcal Proteins PsaA and PspA is Highly Protective against Nasopharyngeal Carriage ofStreptococcus pneumoniaeInfection & Immunity vol. 68 No. 2 (Feb. 2000) p796-800.
Gregor Z. et al, Detection of 23 Immunogenic Pneumococcal Proteins Using Convalescent-Phase Serum Infection & Immunity vol. 68 No. 6 (Jun. 2000) p3740-43 (exact publication date not available).
“Comparison of D1 (Seq ID Nos: 56 and 66) with BVH-11 Seq ID Nos: 7 and 8 of the present invention”.
Spellerberg, et al., “Lmb, a Protein with Similarities to the LraI Adhesin Family, Mediates Attachment ofStreptococcus agalactiaeto Human Laminin”, Infection and Immunity, Feb. 1999, p. 871-878.
Adamou, et al., “Identification and Characterization of a Novel Family of Pneumococcal Proteins That Are Protective Against Sepsis”, Infection and Immunity, Feb. 2001, p. 949-958.
Wizermann, et al., “Use of a Whole Genome Approach to Identify Vaccine Molecules Affording Protection AgainstStreptococcus pneumoniaeInfection”, Infection and Immunity, Mar. 2001, p. 1593-1598.
Zhang, et al., “Recombinant PhpA Protein, a Unique Histidine Motif-Containing Protein fromStreptococcus pneumoniae, Protects Mice against Intranasal Pneumococcal Challenge”, Infection and Immunity, Jun. 2001, p. 3827-3836.
U.S. Appl. No. 09/471,255, filed Dec. 23, 1999, Josee Hamel et al.
U.S. Appl. No. 09/471,255, filed Dec. 23, 1999, Hamel et al.
Hernandez, et al., “Antigenicity of Chimeric Synthetic Peptides Based on HTLV-1 Antigens and the Impact of Epitope Orientation,” Biochemical and Biophysical Research Communication. vol. 276. No. 3, pp. 1085-1088.
Partidos, et al., “The Influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides,” Eur. J. Immunol 1992, 22: pp. 2675-2680.
Oishi, et al., “The effect of amino acid spacers on the antigenicity of dimeric peptide-inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans,” Oral Microbiol Immunol.2001: 16: pp. 40-44.
Kurstak, Edouard, Editorial “Recent progress in vaccines development and new trends in immunisation.” Vaccine 19 (2001) pp. 2198-2200.
Brodeur Bernard
Charland Nathalie
Hamel Josee
Martin Denis
Ouellet Catherine
Ford Vanessa L.
ID Biomedical Corporation
McDermott Will & Emery LLP
Minnifield Nita
LandOfFree
Streptococcus antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Streptococcus antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Streptococcus antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598308